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Ruminants often carry gastrointestinal Shiga toxin (Stx)-producing Escherichia coli (STEC). Stxs belong to
a large family of ribosome-inactivating proteins (RIPs), found in many plants and some bacteria. Plant RIPs,
secreted into extracellular spaces, limit the spread of viruses through plant tissues by penetrating and killing
virally infected cells. Previously, we showed Stx activity against bovine leukemia virus (BLV)-infected cells in
vitro and hypothesized that STEC bacteria have antiviral activity in ruminant hosts. Here, we investigated the
impact of STEC on the initial phases of BLV infection in sheep. Sheep were treated with biweekly oral doses
of E. coli O157:H7 (an STEC) or an isogenic stxmutant strain. A different group of sheep were similarly treated
with five naturally occurring ovine STEC isolates or stx-negative E. coli. Intestinal STEC bacteria were
enumerated and identified by standard fecal culture and DNA hybridization. Oral STEC treatment did not
always result in carriage of STEC, although many animals consistently presented with >104 CFU/g feces. BLV
viremia was assessed by spontaneous lymphocyte proliferation (SLP) in cultures of blood mononuclear cells
and by syncytium formation in cocultures of the same with F-81 indicator cells. SLP was lower (P < 0.05) and
syncytia were fewer (P < 0.05) in STEC-treated sheep than in untreated sheep. Both lower SLP and fewer
syncytia positively correlated with fecal STEC numbers. Average weight gain post-BLV challenge was higher in
STEC-treated sheep than in untreated sheep (P < 0.05). These results support the hypothesis that in
ruminants, intestinal STEC bacteria have antiviral activity and mitigate BLV-induced disease.
Shiga toxin (Stx)-producing Escherichia coli (STEC) bacteria
are a normal part of the gastrointestinal microbiota of domes-
ticated and wild ruminant species, and, as such, are routinely
found worldwide in regional and herd surveys (1, 5, 10, 26,
29–31, 42). STEC bacteria constitute an eclectic group of E.
coli strains, diverse in genomic traits and categorized merely by
the presence of genes for Shiga toxin type 1 (Stx1), Shiga toxin
type 2 (Stx2), and/or Stx2 variants. Some serotypes of STEC
carried by healthy cattle are highly virulent to humans (6, 10,
11), especially the O157:H7 strains, which cause hemorrhagic
colitis and life-threatening sequelae, attributed to the produc-
tion of Stxs by intestinal STEC (11, 14). Although the signifi-
cance of the high frequency of Stx genes in strains of E. coli
colonizing ruminants remains unexplained, it seems reasonable
to expect that Stxs may confer an as-yet-unidentified benefit(s)
to bacteria and/or to their carriers. For example, Stxs may have
an impact on bovine tissues colonized by STEC: the Stx recep-
tor, globotriaosylceramide, is present on bovine intestinal ep-
ithelium but not on vascular cells (23), and colonization of
bovine intestine by O157:H7 is associated with a reduced turn-
over rate of enterocytes, without an increase in the apoptotic
rate (35).
Stxs belong to a large family of ribosome-inactivating pro-
teins (RIPs), found in many plants and in some bacteria (15,
47). The RIPs may be hemitoxins, comprised of only a single A
chain with N-glycosidase activity specific for rRNA (15), or
holotoxins of ABn structure, composed of the enzymatically
active A subunit and a specific number (n) of B subunits that
bind cellular toxin receptors. The N-glycosidase activity depuri-
nates rRNA and results in an inhibition of target cell protein
synthesis. Plant RIPs are primarily hemitoxins, whereas bacterial
RIPs are holotoxins of AB5 structure. The plant RIPs are se-
creted into extracellular spaces and limit the spread of plant
viruses through their tissues by penetrating and killing virally
infected cells. Many plant RIPs are highly toxic to virally infected
animal cells in culture at concentrations that do not affect the
uninfected cells (34, 40). The virally infected plant and animal
cells are thought to internalize the toxins through virus-induced
permeable cell membranes (9), independent of receptor-medi-
ated endocytosis. Thus, antiviral effects may be exerted by the
enzymatic portion of an RIP molecule alone, e.g., the A subunit
of ricin has activity in vitro against cells infected with the human
immunodeficiency virus (55). The enzymatic A subunit of Stx1
suppresses bovine leukemia virus (BLV)-induced spontaneous
lymphocyte proliferation (SLP) and reduces the output of BLV
particles in bovine cell culture (3, 16, 17). Based on these results,
we hypothesized that Stxs, produced by intestinal STEC, have
antiviral activity in ruminant carriers and that this activity may
reduce the severity of infections with BLV and other viruses or
delay an onset of the acute stage of viral disease. This hypothesis
was tested here by assessing BLV viremia in experimentally in-
fected sheep treated or not treated with STEC.
BLV is an oncogenic retrovirus responsible for the enzootic
form of bovine lymphosarcoma (18). In cattle, BLV infection
may be asymptomatic for 1 to 7 years and then progress to a
persistent lymphocytosis that is characterized by a neoplasia of
B lymphocytes (45). Most cattle at this stage remain free of
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disease symptoms, but some may progress to a polyclonal B-
cell lymphoma and then to the end stage of disease, lympho-
sarcoma. Although not naturally occurring, BLV infection can
be experimentally induced in sheep and results in a more rapid
progression of disease than it does in cattle, and lymph node
pathology and other clinical signs of disease can be observed
6 to 12 months after exposure to an infectious dose of BLV
(13, 28).
Because sheep, like cattle, naturally carry intestinal STEC
and because sheep exhibit a relatively rapid progression of
experimentally induced BLV disease, we investigated the im-
pact of STEC on the initial phases (more than 3 months) of
BLV infection in sheep. Two experiments were carried out.
First, sheep were treated with repeated oral doses of STEC or
an isogenic stx deletion strain. Second, a different group of
sheep were similarly treated with five naturally occurring ovine
STEC isolates or stx-negative E. coli. Treatments began before
or 24 h after BLV challenge, and intestinal STEC bacteria
were enumerated and identified by standard fecal culture and
DNA hybridization. Viremia and viral load in peripheral blood
mononuclear cells (PBMC) were measured by SLP in PBMC
cultures and induction of syncytia in cocultures of PBMC with
F-81 indicator cells. Also, weight gain was monitored as an
indicator of general health.
MATERIALS AND METHODS
Experimental animals. White-face Suffolk wethers, 3 to 4 months old, were
purchased from a local supplier (Rickwood Sheep Farm, Priest River, Idaho)
and acclimatized for 3 weeks before commencement of the experiment. The
sheep were housed in a containment facility at the University of Idaho and given
alfalfa hay once daily and water ad libitum. All animals were dewormed by oral
application of Valbazen (Pfizer Inc., New York, NY) and tested negative for
BLV and bluetongue virus before challenge.
Enumeration of the intestinal STEC. Fecal samples were obtained by rectal
palpation, chilled and held on ice, and transported to the laboratory within 1 h
of collection. Five grams of feces was added to 45 ml peptone-Tween diluent
(PT; 0.1% peptone, 1% Tween 80) and vortexed thoroughly. The fecal suspen-
sion was prefiltered through coarse, sterile, cotton gauze to remove gross debris.
The gauze was flushed with 50 ml PT to maximize bacterial carriage into the
prefiltrate. The prefiltrate was decimally diluted in PT, and appropriate dilutions
(typically 101 and 102 of the prefiltrate) were filtered onto hydrophobic grid
membrane filters (HGMFs) (Isogrid membranes; Neogen, Lansing, MI) using a
spreadfilter (Filtaflex, Almonte, ON, Canada) and a vacuum manifold. HGMFs
were incubated at 37°C face up on hemorrhagic colitis agar (50), modified from
the original formulation, to detect all STEC bacteria by the omission of 4-methy-
lumbelliferyl--D-glucuronide (MUG), 1% cefsulodin, and 0.1% potassium tel-
lurite, as these supplements were specific to the isolation of the O157:H7 sero-
type. Colonies on each HGMF were replicated onto another HGMF using an
HGMF replicator/inoculator system (Filtaflex). Replicate membranes were in-
cubated as described above and stored at 4°C for isolate recovery and in case
repeat hybridizations were required. Bacterial cells on original HGMFs were
lysed following the method of Nizetic et al. (39) after the wetting of membranes
with a pretreatment solution for 30 min (57). DNA was fixed to the membranes
by exposure to UV radiation for 5 min. HGMFs with adherent DNA were
hybridized with a combined probe for stx1 and stx2 produced using PCR (PCR
DIG Probe synthesis kit; Roche Diagnostics, Indianapolis, IN) with the primers
described by Karch and Meyer (27). Colony blot hybridization was performed
using standard methods (DIG System User’s Guide to Filter Hybridization;
Roche) with a Robbins Scientific model 1000 hybridization oven/shaker (Sunny-
vale, CA), and hybridized membranes were color developed using standard
methods (DIG nucleic acid detection kit; Roche). Final STEC counts for fecal
samples (in the form of CFU/g) were based on the count of positive colony blots
on hybridized membranes corresponding to typical E. coli colonies on replicate
membranes, multiplied by the respective dilution factor.
Detection of stx using PCR. In order to positively identify samples not har-
boring enough STEC bacteria to be detectable by the STEC enumeration pro-
tocol, the presence of the toxin gene stx was used as an indicator for STEC. Fecal
samples were enriched by adding 1 g to 49 ml of E. coli broth (Remel, Lenexa,
KS) containing 0.02 mg/ml novobiocin (Sigma-Aldrich, St. Louis, MO) and
incubating them for 18 h at 37°C. Boiled cell lysates made from centrifuged
pellets of enriched sample were serially washed and resuspended in 200 l
distilled H2O before being screened for the presence of stx using PCR (27). The
PCR mixture included 0.25 U Taq DNA polymerase, 2 mM MgCl2, 200 M each
deoxynucleoside triphosphate, 0.1 M of the forward and reverse primers (all
reagents from Invitrogen Life Technologies, Carlsbad, CA), and 400 g/ml
bovine serum albumin (Sigma) per reaction. A 2-l aliquot of DNA template was
added to 23 l of reaction mixture. Reactions were performed using an iCycler
thermal cycler (Bio-Rad, Hercules, CA), and gel images were stored digitally
using the Gene Genius imaging system (Syngene, Cambridge, United Kingdom).
Bacterial strains. Two separate groups of STEC strains were used in the two
experiments. The first experiment was performed with E. coli O157:H7 905 and
its toxin-negative derivative. E. coli O157:H7 905, an Stx2-producing clinical
isolate from a patient with hemolytic-uremic syndrome, and a kanamycin resis-
tance derivative, with a deletion of stx2 made by the  Red recombinase system
(12), were kindly provided by M. Waldor (Tufts-New England Medical Center
and Howard Hughes Medical Institute, Boston, Mass.) (43). Prior to use in
sheep, the kanamycin resistance gene in the stx2 mutant was removed by intro-
ducing pCP20. The second experiment was performed with five naturally occur-
ring ovine STEC isolates and stx-negative E. coli K-12. The five ovine STEC
serotypes were obtained in an earlier study and included O5 stx1-negative stx2-
positive (two isolates), O5 stx1-positive stx2-positive, O91 stx1-positive stx2-nega-
tive, and a nontypeable isolate, ONT stx1-positive stx2-positive (31). All bacteria
were grown separately overnight at 37°C, with shaking in Luria-Bertani medium,
chilled on ice, and administered orally to sheep in total doses of 5  1010 CFU,
either singly or as a mixture of five ovine isolates, mixed immediately prior to dosing.
BLV challenge. BLV-positive PBMC were obtained from a seropositive BLV
donor, cow no. 2062, housed at the University of Idaho dairy. The donor was in
the persistently lymphocytotic stage of BLV infection, as determined by elevated
numbers of peripheral B lymphocytes and the occurrence of SLP in cultures of
purified PBMC (data not shown). PBMC were purified from blood samples by
density centrifugation on Accupaque (1.086 g/ml; Accurate Chemical and Sci-
entific Corp., Westbury, N.Y.), followed by hypotonic lysis of erythrocytes and
repeated washing in phosphate-buffered saline (PBS). To determine the optimal
dose of PBMC to induce BLV infection, nine sheep were separated into three
groups and received a subcutaneous injection of 1 106, 1 107, or 5 107 total
PBMC. Control animals were injected with PBS. Based on the outcome of this
challenge, 1.0  106 PBMC were chosen as the optimum BLV dose used in
subsequent experiments. Establishment of BLV infection was determined by
measuring anti-BLV antibodies by agar immunodiffusion assay at the Washing-
ton Animal Disease Diagnostic Laboratory (Washington State University, Pull-
man, WA).
Experimental design. Two experiments were performed with separate groups
of BLV-naive sheep. The first (experiment I) used treatment with isogenic strains
of E. coli with or without stx to establish the toxin as the required feature of the
E. coli strain. The second (experiment II) used naturally occurring ovine STEC
strains in an effort to improve the persistence of STEC in the ovine gastrointes-
tinal tract. In both experiments, sheep were semirandomly assigned to four
treatment groups to preclude clustering of littermates and animals with high and
low birth weights in the same groups. All animals were orally dosed with bacteria
twice per week for the duration of the experiment, and the groups were housed
without physical contact between groups.
Experiment I was a shorter-term 8-week experiment and consisted of four
groups of animals: four sheep in group 1 were treated with wild-type E. coli
O157:H7 905 (stx2); four sheep in group 2 were treated with the engineered
isogenic stx2 deletion mutant; three sheep in each of groups 3 and 4 were treated
with toxin-negative E. coli K-12. Groups 1, 2, and 3 were challenged with BLV,
and group 4 served as healthy controls with no BLV challenge.
Experiment II was a longer-term (3 months) experiment and consisted of
four groups with five sheep in each group. Groups 1 and 2 were treated with a
mixture of five ovine STEC strains; groups 3 and 4 were treated with stx-negative
E. coli K-12. As in experiment I, groups 1, 2, and 3 were challenged with BLV.
Group 1, referred to as “pre- and post-BLV STEC,” was treated with oral STEC
both prior to and post-BLV challenge, beginning 14 days before BLV challenge
and ending at the conclusion of the experiment. Group 2, named “post-BLV
STEC,” received stx-negative E. coli K-12 prior to BLV challenge and was
treated with STEC only postchallenge, beginning 24 h after BLV challenge and
continuing through the end of the experiment. Groups 1 and 2 were treated
jointly in some analyses and are referred to as “STEC-treated groups.” Groups
3 (named “BLV no STEC”) and 4 (named “no BLV”) were treated with stx-
negative E. coli K-12.
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PBMC and serum preparation. Blood samples were obtained 1 week before
BLV challenge, weekly for the first 8 weeks post-BLV and monthly thereafter.
Venous blood was collected into 20-ml vacuum tubes with 4.0 ml of acid citrate
dextrose and chilled on ice. Serum samples were obtained from coagulated blood
collected into untreated vacuum tubes. PBMC were purified as described previ-
ously (17). In brief, blood samples were centrifuged for 30 min at 450  g at 4°C,
and buffy coats were layered on Accupaque (1.086 g/ml) and centrifuged for 30
min at 1,000  g at 16°C. PBMC were washed with PBS-EDTA, contaminating
erythrocytes and platelets were removed by brief water lysis, and cells were
rescued with 10 PBS and counted using a hemocytometer. The density of
PBMC was adjusted to 1.0 107 cells/ml in PBS with 1% bovine serum albumin,
and the cells were stored on ice until being transferred to culture vessels imme-
diately prior to incubation.
SLP assay. Quadruplicate PBMC samples at 5.0 105 cells/well in 200 l were
cultured in 96-well plates at 37°C with 6.5% CO2 in RPMI 1640 medium (Gibco
BRL) supplemented with antibiotics, L-glutamine, and 20% fetal bovine serum.
After 48 h, 1 Ci/well of 3H-thymidine (Moravek Biochemicals, Brea, CA) was
added to cultures, and 16 to 18 h later, the cells were harvested onto glass filters
using a Filtermate Packard harvester (Packard Instrument Company, Meriden,
CT) and counted using a Packard scintillation counter, TopCount NXT.
Syncytium induction assay. The syncytium induction assay was a modification
of an enumeration assay for the BLV-positive PBMC from experimentally in-
fected sheep (33). Feline epithelial F-81 cells were kept frozen in liquid nitrogen
and freshly thawed for each assay. The cells were washed in PBS-EDTA-0.5%
bovine serum albumin, counted using a hemocytometer, and distributed into
24-well culture plates at 5.0  103 or 10  103 viable cells/well. Viability of the
cells was 95%, as determined by trypan blue exclusion. The cells were cultured
overnight at 37°C with 6.5% CO2 in RPMI 1640 medium with 13% FBS, sup-
plemented with L-glutamine and antibiotics. The next day, 1.0  105 or 1.0  106
PBMC, purified from blood samples as described above, were added to the
culture wells. The cocultures were incubated for 48 h, rinsed with PBS, and
cultured with fresh medium for an additional 2 to 3 days. When confluence
reached 60 to 80% and well-developed syncytia could be seen, the cultures were
rinsed with PBS, fixed with absolute methanol, stained with Giemsa, and exam-
ined microscopically. Syncytia with more than six nuclei were considered to be
induced by BLV.
Flow cytometry. Blood leukocytes were purified by water lysis of 200 l of
whole blood and rescue of the cells with 10 PBS. The cells were washed with
PBS-EDTA and incubated (30 min at 4°C, PBS-EDTA-1% horse serum) with
primary mouse monoclonal antibodies (5.0 g/ml) to the B-cell markers B-B1
and B-B2 (BAS9A and BAQ44A, immunoglobulin M [IgM]) and to BLV protein
gp51 (MW1, IgG1), from the Washington State University Monoclonal Antibody
Center, Pullman, WA. The cells were washed thrice, incubated for 30 min as
described above, but with goat anti-mouse polyclonal antibodies conjugated to
fluorescein isothiocyanate (anti-IgM) or to Tri-Color (anti-IgG1) (Caltag Labo-
ratories, Burlingame, CA), washed twice with PBS, and fixed with 2% formal-
dehyde in PBS. Flow cytometry data were acquired for 20 103 to 30  103 cells
per sample, using a FACSCalibur flow cytometer equipped with an argon laser
at 488 nm (BD Biosciences, San Jose, CA).
Statistical analysis. All counts were analyzed after a square root transforma-
tion, and differences among groups were tested by analysis of variance using
Tukey’s method for comparisons of BLV-challenged groups and Dunnet’s
method for comparisons with the control. The frequencies of high and low fecal
STEC counts were analyzed by the chi-square test. Pearson’s correlation coeffi-
cients were calculated to assess correlation between parameters of viremia and
the numbers of fecal STEC strains, and the lines of best fit were calculated when
correlation was statistically significant, i.e., 0.05. Observations were clustered
using McQuitty’s linkage and Pearson’s method for distance calculation. The
average values presented in this paper are accompanied by standard errors of the
means (SEMs). Statistical analysis was performed using the Minitab 13 program
(Minitab Inc.).
RESULTS
The infecting dose of 1  106 PBMC from the BLV-positive
cow was selected as the lowest dose that resulted in prompt
seroconversion of the sheep (data not shown). Sheep did not
have complications unrelated to BLV challenge (those with
abnormal postmortems showed signs compatible only with
BLV infection, such as lymph node enlargement and tumors),
and examination of biweekly blood smears showed eosinophil
counts of 5%, indicating that the animals did not carry sig-
nificant worm burdens. All sheep challenged with BLV sero-
converted within 1 month of challenge, and none of the control
sheep became seropositive (data not shown). The naturally
occurring numbers of fecal STEC bacteria, first determined
within 1 week of arrival to the housing facility, varied among
sheep, from undetectable to 106 CFU/g feces, and subse-
quently were liable to alternate between high and low values
(data not shown). The presence of fecal STEC among animals
that were not given oral STEC was due to these naturally
occurring strains.
Stx mediates antiviral effects of STEC in sheep. (i) Experi-
ment I. We compared the initial aftermaths of BLV challenge
among three groups of sheep orally treated biweekly with 5 
1010 CFU of wild-type E. coli O157:H7 905 (group 1), the E.
coli 905 isogenic stx2 deletion mutant (group 2), or stx-negative
E. coli K-12 (infection control, group 3). We observed striking
differences between animals treated with STEC (group 1) and
animals treated with stx-negative E. coli (groups 2 and 3) in
such indicators as weight gain during the BLV incubation pe-
riod (Fig. 1) and SLP of PBMC in culture (Fig. 2). Sheep
treated with STEC (group 1) gained 5 to 20% of weight over
the first 2 weeks post-BLV challenge, whereas only two of
seven animals treated with stx-negative E. coli (groups 2 and 3)
gained as much weight. These differences were correlated with
better feed consumption among STEC-treated animals and
indicated their general well-being. Group 4 animals were not
challenged with BLV and maintained their weight as expected
for this age. SLP, an indicator of viral load, increased in sheep
treated with the stx2 deletion mutant and in the BLV infection
control animals that received E. coli K-12 (group 3). In con-
trast, SLP did not increase above healthy control levels in the
group of sheep treated with STEC. The improved weight gain
and lower SLP values for animals in group 1 were apparently
FIG. 1. Increased weight gain in sheep treated with STEC. Four
groups of sheep received biweekly oral doses of bacteria, and three
groups were challenged with BLV. Group 1 received STEC, E. coli
O157:H7 strain 905, group 2 received an isogenic stx2 deletion mutant
of strain 905, and groups 3 and 4 received stx-negative E. coli K-12.
Data are percentages of weight changes of the sheep during first 2
weeks of bacterial treatments and post-BLV challenge. Solid circles
show data for individual animals, and cross bars show median values
for groups. The broken line at 0 indicates no weight change.
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related to the stx2 in E. coli O157:H7 905. The fact that data
points were similarly clustered in groups 2 and 3 (Fig. 1 and 2)
indicated that responses of sheep to BLV challenge were not
greatly influenced by the multitude of non-stx genes present in
the stx2 deletion mutant or toxin-negative E. coli K-12.
During the first month post-BLV challenge, only two ani-
mals in group 1, treated with the human E. coli strain 905,
presented with high total numbers of fecal STEC bacteria.
These two animals had a 4-log augmentation of total fecal
STEC counts, with averages of 106 CFU/g of feces compared to
fecal STEC counts among animals in groups 2 and 3 that had
an average of 102 CFU STEC/g feces (data not shown). The
oral dosing of STEC, even without persistence of the bacteria
in the gastrointestinal tract, had measurable effects. Two ani-
mals in group 1 that tested fecal STEC negative during the first
3 weeks of oral treatment showed increases in weight and low
SLP (Fig. 1 and 2 and data not shown), similar to the STEC-
positive animals in that group. This suggested that the Stx2
protein present in the preparations of bacteria and/or secreted
during passage of inocula through the intestine contributed to
the observed antiviral effect.
The absence of STEC in fecal samples from some animals in
group 1 indicated a poor ability of the human isolate E. coli
O157:H7 905 to persist and/or colonize the ovine intestine.
This was also evident in the inability of the stx2 deletion mutant
to displace naturally occurring STEC, as three animals in group 2
remained STEC positive at low levels (103 CFU STEC/g feces)
for at least 2 weeks of oral treatment (data not shown). Thus, in
an effort to better augment gastrointestinal STEC by oral bacte-
rial treatments, naturally occurring ovine STEC strains were used
in experiment II.
(ii) Experiment II. Similar to experiment I, experiment II
compared the initial aftermaths of BLV challenge among
groups of sheep orally treated biweekly with 5  1010 CFU of
bacteria but employed ovine STEC isolates to more closely
mimic the natural situation, in hopes of improving the persis-
tence of the treatment strains in the gastrointestinal tract.
Groups 1 and 2 received five naturally occurring ovine STEC
strains, and groups 3 and 4 received stx-negative E. coli K-12.
Group 1 animals were treated with STEC prior to and post-
BLV challenge to increase the likelihood of the presence of
STEC and/or Stxs in animals at BLV challenge. Group 2 re-
ceived STEC beginning at 24 h post-BLV challenge to deter-
mine whether STEC postchallenge would affect viral disease.
Group 3 was the infection control, and group 4 was a healthy
control not infected with BLV.
Oral treatment with ovine bacteria had limited impact on
gastrointestinal colonization by STEC. The total numbers of
naturally occurring intestinal STEC bacteria in the sheep var-
ied widely and frequently changed considerably, as can be
ascertained from fecal STEC numbers obtained before and
after bacterial treatment (Fig. 3). However, average carriage
among untreated sheep was usually 	104 CFU STEC/g feces.
Similar to the results of experiment I, STEC treatment was not
always associated with stable carriage of STEC, and some
animals occasionally did not present with detectable fecal
STEC in spite of the repeated applications of ovine strains.
Among the two STEC-treated groups, individuals clustered in
two categories: three animals in each group consistently pre-
sented with high total numbers of STEC bacteria (104 CFU/g
feces) post-BLV challenge, while STEC numbers were low in
the remaining two animals in each group (Fig. 3A and B). In
the BLV group without STEC, two animals spontaneously
acquired and maintained high total numbers of STEC bacteria
(104 CFU/g) throughout the post-BLV-challenge period. Im-
portantly, the STEC treatment given to animals before and
after BLV challenge was associated with relatively high total
numbers of fecal STEC bacteria in samples immediately pre-
ceding (average log value, 3.32) and following (average log
value, 4.47) BLV challenge (Fig. 3A), whereas the counts for
the group treated only postchallenge were lower before BLV
challenge (average log value, 1.71) but relatively high after it
(average log value, 3.91) (Fig. 3B). Just before BLV challenge,
the total number of fecal STEC bacteria in animals not treated
with STEC bacteria was substantially lower than that among
the STEC-treated groups, with average log values of 1.46 and
0.80 (Fig. 3C and D, respectively). Thus, despite variations in
STEC carriage, STEC-treated groups were consistent with the
experimental design to test the effect of high numbers of STEC
bacteria before and during BLV challenge or the effect of high
numbers of STEC bacteria following BLV challenge, and both
groups differed from the untreated controls.
Based on the results in experiment I that indicated that
STEC treatment had an effect on BLV disease despite the
apparent lack of bacterial colonization and that showed a dif-
ficulty in consistently changing the total number of fecal STEC
bacteria, we used a two-prong approach and analyzed the re-
sults first between treatment groups, regardless of fecal STEC,
and second between animals, taking into account individual
total numbers of fecal STEC bacteria.
Ovine STEC treatment decreased BLV load as measured by
SLP. BLV-dependent SLP in cultures of PBMC from BLV-
positive animals requires, and is preceded by, expression of
FIG. 2. Oral STEC treatment prevents SLP increase in cultured
PBMC. Four groups of sheep received biweekly oral doses of bac-
teria, and three groups were challenged with BLV. Group 1 re-
ceived STEC, E. coli O157:H7 strain 905, group 2 received an
isogenic stx2 deletion mutant of 905, and groups 3 and 4 received
stx-negative E. coli K-12. Solid circles show mean values from four
replicate cultures for individual animals, and cross bars show me-
dian values for groups. The broken line indicates the median value
for the healthy control group.
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BLV proteins by cultured cells and thus can serve as an indi-
rect measure of BLV load (17, 51, 52). During the first 3 weeks
post-BLV challenge, SLP levels in cultures from all BLV-
challenged sheep were similar to those of the healthy control
group and represented the incubation period of BLV infection
(Fig. 4A). However, at 4 weeks post-BLV challenge, SLP in
cultures from all challenged sheep increased by 130 to 880%,
and group averages were higher than those of the healthy
controls (P  0.05), indicating a progression of viral disease.
By 7 weeks postchallenge, SLP values returned to normal lev-
els in all animals, consistent with the chronic asymptomatic
phase of the disease. The group average SLP did not reveal
differences between BLV-challenged groups because individ-
ual SLP values peaked at different times between 4 and 6
weeks post-BLV challenge, thus, individual maximal SLP
counts (SLP-max) were used in further analyses. Individual
SLP-max from the infection control (BLV without STEC) and
the healthy control (no BLV) did not overlap (P  0.05) (Fig.
4B). SLP-max for most sheep (three out of five) in both STEC-
treated groups were within the range of the healthy control
group values, and these groups differed from the BLV group
without STEC (P  0.05) after the exclusion of the single
outliers (sheep 1381 and 1389).
Fecal STEC correlated with decreased BLV load as mea-
sured by SLP. Among all 10 STEC-treated sheep, three of the
four highest SLP-max occurred in cultures from animals pre-
senting exceptionally low total counts of fecal STEC bacteria
(Fig. 4B), whereas among five sheep in the BLV group without
STEC, two of the three with the lowest SLP-max occurred in
animals presenting exceptionally high counts of STEC bacteria
(Fig. 4B), indicating that SLP-max were inversely related to the
numbers of intestinal STEC bacteria. This conjecture was con-
firmed by analysis of SLP-max in the context of fecal STEC
numbers during BLV incubation (day 5 post-BLV challenge)
and during active infection (day 26 post-BLV challenge). The
six sheep in the two STEC-treated groups that presented with
SLP-max within the healthy control group range (Fig. 4B) also
collectively presented with 104 CFU STEC/g in 8 of 12 fecal
samples (67%). Conversely, only one sample with104 CFU/g
was found among eight samples (13%) from the four remain-
ing animals, with an SLP-max exceeding that of the control
FIG. 3. The effect of oral bacterial treatment on the total number of fecal STEC bacteria. The number of STEC CFU/g feces was determined
by colony hybridization and PCR. Four experimental groups are shown that were treated with biweekly oral doses of 5 1010 CFU bacteria/animal.
Two groups received STEC starting 2 weeks before BLV challenge (pre & post BLV STEC group) (A) or starting 24 h post-BLV challenge (post
BLV STEC group) (B) and continuing for 16 weeks post-BLV challenge. Two groups received E. coli K-12 starting at week 2. The infection
control group received BLV (BLV no STEC) (C), and the healthy control group was not challenged with BLV (no BLV) (D). Within each group,
two subgroups of three (solid circles) or two (empty circles) animals were identified that had similar STEC counts (animal identifiers in key). The
samples that were STEC positive by PCR but had no hybridization counts were assigned a value of 10 CFU/g feces. A solid arrow indicates
commencement of biweekly STEC treatment, and a stippled arrow indicates the single injection of sheep with BLV. A horizontal solid line at log
4 separates CFU counts considered high (above log 4) and those considered low (below log 4).
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group. This suggested that a fecal STEC density of 104
CFU/g feces had a mitigating effect on BLV infection.
This supposition was further confirmed by plotting SLP-max
against fecal STEC counts averaged over a 2-month period
post-BLV challenge (Fig. 5A). Thus, SLP-max for five out of
six STEC-treated animals presenting an average count of fecal
STEC bacteria of 104 CFU/g were within the range of healthy
control group SLP-max (Fig. 5A, upper left quadrant). Con-
versely, only one of four SLP-max from STEC-treated animals
presenting average fecal STEC counts of 104 CFU/g was
within the range of that of the healthy control group (Fig. 5A,
lower left quadrant) (Pearson’s correlation coefficient 

0.774, P 
 0.003). Importantly, there was no correlation
between fecal STEC counts and SLP-max among individuals of
the healthy control group, indicating that in the absence of
BLV infection, intestinal STEC bacteria do not influence SLP.
FIG. 4. Ovine STEC treatment prevents SLP increase in cultured PBMC. Cell proliferation was measured as the incorporation of tritiated
thymidine and expressed as kCPM. Four experimental groups are shown that were treated biweekly with oral doses of 5  1010 CFU bacteria/
animal. Two groups received STEC, starting 2 weeks before BLV challenge (pre & post BLV STEC, group 1) or starting 24 h post-BLV challenge
(post BLV STEC, group 2) and continuing for 16 weeks post-BLV challenge. Two groups received E. coli K-12 starting at week 2. The infection
control group received BLV (BLV no STEC, group 3), and the healthy control group was not challenged with BLV (no BLV, group 4). (A) Data
are means  SEMs of cultures from five sheep. The horizontal broken line indicates the average background proliferation in PBMC cultures prior
to BLV challenge. (B) The maximal SLP values were obtained between 4 and 6 weeks post-BLV challenge. Data are median kCPM values per
four culture replicates (cross bars) and 95% confidence intervals for medians (boxes). The horizontal dotted line indicates the upper range of SLP
in the healthy controls (group 4), and the star indicates a statistically significant difference from this group (P  0.05). Light stipple indicates the
animals that had zero or103 CFU/g (low) fecal STEC counts despite STEC treatment, and heavy stipple indicates animals in the untreated group
that had 104 CFU/g (high) fecal STEC counts.
FIG. 5. Suppression of BLV-induced SLP correlated with the total numbers of fecal STEC bacteria. Three experimental groups are shown that
were treated biweekly with oral doses of 5  1010 CFU bacteria/animal. Two groups received STEC, starting 2 weeks before BLV challenge (pre
& post BLV STEC, group 1) or starting 24 h post-BLV challenge (post BLV STEC, group 2) and continuing for 16 weeks post-BLV challenge.
The infection control group (BLV no STEC, group 3) received E. coli K-12 starting at week2. All three groups were challenged with BLV. Fecal
STEC counts, averaged over a 2-month period post-BLV challenge and expressed as the logs of CFU/g, are plotted against kCPM per culture
(A) or against kCPM per 105 B cells in culture (B). Horizontal solid lines at log 4 separate CFU counts considered high (above log 4) and those
considered low (below log 4). Vertical lines indicate the upper ranges of background SLP in the healthy control group. Data points were fitted with
cuboidal polynomial lines (R2 values shown) after the exclusion of outliers with fecal STEC numbers inconsistent with treatment (points in
brackets).
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The data points in Fig. 5A were fitted with a cuboidal polyno-
mial line, indicating that the inverse correlation between fecal
STEC numbers and SLP-max was linear for fecal STEC within
a range of 1.0 to 4.5 log CFU/g.
Since BLV is expressed only in B cells (37), it was expected
that SLP would be proportional to the numbers of B cells in
the PBMC samples. When SLP-max were expressed as kilo-
counts per minute (kCPM) per 105 B cells in culture, the
protective effect of STEC became more apparent (Fig. 5B).
Thus, B-cell-corrected SLP-max for all 8 of 15 BLV-challenged
animals that presented with a high average total fecal STEC
count of 104 CFU/g were within the range of that of the
healthy control group, irrespective of STEC treatment (Fig.
5B, upper left quadrant). Conversely, among the seven remain-
ing BLV-challenged animals presenting a low average total
fecal STEC count of 104 CFU/g, four of the B-cell-corrected
SLP-max were above the range of that of the healthy control
group (Fig. 5B, lower right quadrant). A cuboidal polynomial
line of best fit again indicated an inverse correlation between fecal
STEC numbers of 1.0 to 4.5 log CFU/g and B-cell-corrected
SLP-max.
Ovine STEC treatment correlated with decreased BLV load
as measured by formation of syncytia. BLV particles released
from BLV-expressing cells induce syncytia in cultures of fu-
sion-prone indicator cells, such as F-81 (53). F-81 cells were
cocultured with PBMC from BLV-challenged sheep, and syn-
cytia with more than six nuclei were enumerated as BLV in-
duced. Smaller syncytia with fewer nuclei were not counted, as
they spontaneously formed in cultures of F-81 cells alone and
in cocultures with PBMC from the healthy control sheep that
had no large multinucleated syncytia typical of BLV-induced
cell fusions (data not shown). PBMC from BLV-challenged
sheep did not induce syncytia for the first 2 weeks postchal-
lenge, consistent with the incubation period of BLV disease. At
3 weeks post-BLV challenge, when indicator cells were cul-
tured with low numbers of 1.0  105 PBMC, only one syncy-
tium was found in all cocultures from the group treated with
STEC prior to and post-BLV challenge, but seven syncytia
were found in all cocultures from the group treated with STEC
only post-BLV challenge, and four syncytia were found in all
cocultures from the infection control group (data not shown).
PBMC from the same blood samples, applied in larger num-
bers (1.0  106), induced syncytia in all cultures from BLV-
challenged sheep. However, in each of the STEC-treated
groups, there were only two of five cultures with at least four
syncytia, whereas in the infection control group, there were
four of five cultures with at least four syncytia (data not
shown). At 3 months post-BLV challenge, 106 PBMC induced
syncytia that were too numerous to count, indicating an in-
creased BLV load in the sheep compared to that at 3 weeks
postchallenge, but syncytia were countable when 105 PBMC
were used. Thus, cultures from the group treated with STEC
before and after BLV challenge showed 0 to 4 syncytia (2.2 
0.7), and the cultures from the group treated with STEC post-
BLV challenge showed 2 to 6 syncytia (3.6  0.7), but the
cultures from the infection control group showed 4 to 16 syn-
cytia (9.0  2.1) (first and last groups, P  0.05). These results
suggest that STEC treatment lowered BLV load.
Analogous with SLP, it could be expected that BLV-induced
syncytia would be proportional to the number of B cells in the
cocultures. Accordingly, we calculated the number of B cells
needed to induce one syncytium by dividing the number of B
cells present in an F-81/PBMC coculture by the number of
syncytia. At 3 weeks and 3 months post-BLV challenge, more
B cells were needed to induce one syncytium from both STEC-
treated groups than for the infection control group (Table 1).
These results indicated that the BLV load was lower among
sheep that received STEC treatment. By 3 months, the differ-
ences in viral load were twofold and fourfold less than that of
the infection control for the group that received STEC treat-
ment after BLV challenge and the group that received treat-
ment before and after challenge, respectively (Table 1). This
suggested that STEC treatment was the most effective in re-
ducing BLV load when it was initiated before BLV challenge.
Fecal STEC correlated with decreased BLV load as mea-
sured by formation of syncytia. The plot of B-cell numbers per
induced syncytium versus total fecal STEC numbers confirmed
that B cells from sheep that presented with high STEC num-
bers induced fewer syncytia than B cells from sheep presenting
with low STEC numbers. The optimal clustering of data points
divided them among four quadrants, as shown in Fig. 6, sug-
gesting that total fecal STEC counts of 104 CFU/g were
required, although not always sufficient, for reduction of the
numbers of syncytia. At 3 weeks post-BLV challenge, in six of
seven cocultures from sheep presenting with total fecal STEC
numbers of104 CFU/g, (101 10) 103 B cells were needed
to induce one syncytium (Fig. 6A, lower left quadrant). Con-
versely, in five of eight cocultures from sheep presenting with
total fecal STEC numbers of 104 CFU/g, (300  51)  103 B
cells were needed to induce one syncytium (Fig. 6A, upper
right quadrant). The data points could be fitted with a cuboidal
polynomial line similar to the one in Fig. 5A, indicating that
the inverse correlation between fecal STEC numbers and the B
cells needed to induce one syncytium was linear for total fecal
STEC numbers within a range of 2 to 5 log CFU/g.
At 3 months post-BLV challenge, a correlation between
numbers of the fecal STEC and of B cells per syncytium was
noted only in STEC-treated groups. Thus, in three cocultures
from sheep presenting with total fecal STEC numbers of 104
CFU/g, (6.0  0.3)  103 B cells were needed to induce one
syncytium (Fig. 6B, lower left quadrant). Conversely, in five of
six cocultures from sheep presenting with total fecal STEC
numbers of 104 CFU/g, twice that number of B cells [(14.5 
2.3)  103] was needed to induce one syncytium (Fig. 6B,
TABLE 1. Number of B cells per BLV-induced syncytium in
cocultures of ovine PBMC and F-81 indicator cells
Exptl group
Time post-BLV
challenge (no.
of PBMC)b
No. of B
cells/syncytiuma
Pre- and post-BLV STEC 3 wk (106) (2.0  0.8)c  105
Post-BLV STEC (1.9 0.6)  105
BLV without STEC (1.4  0.5)c  105
Pre- and post-BLV STEC 3 mo (105) (13.0  0.3)c  103
Post-BLV STEC (8.7 2.4)  103
BLV without STEC (3.2  0.7)c  103
a Values are means  SEMs of five F-81/PBMC cocultures.
b Number of cells used per F-81/PBMC coculture.
c These values were significantly different by analysis of variance (P  0.05).
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upper right quadrant). A cuboidal polynomial line could be
fitted for the data points of STEC-treated groups, indicating
that an inverse correlation between total fecal STEC numbers
and the B cells needed to induce one syncytium was linear for
fecal STEC within a range of 1.5 to 4.5 log CFU/g. This line
reached a plateau above 4 logs, again supporting the conjec-
ture that fecal STEC numbers of 104 CFU/g were necessary
to reduce the BLV load in B cells. Notably, regardless of STEC
treatment, PBMC obtained from all sheep presenting with
105 CFU/g at least once post-BLV challenge (sheep 1393,
1422, 1432, and 1433) induced no more than three syncytia per
coculture at 3 weeks post-BLV challenge, whereas PBMC from
8 of the 12 remaining sheep that never presented with 105
CFU STEC/g feces (sheep 1373, 1385, 1399, 1395, 1404, 1412,
1420, and 1424) induced at least four syncytia per culture.
These results suggest that animals that presented with total
fecal STEC numbers of 105 CFU/g at least once during the 2
months post-BLV challenge had a reduced BLV load.
Oral application of STEC promoted post-BLV weight gain
in sheep. As in experiment I, weight gain was used as an
indicator of general health and well-being. Between 4 and 7
weeks post-BLV challenge, the animals in the STEC-treated
groups gained more weight than untreated animals. The aver-
age weight gains (kg) were 4.9  1.3 in the group treated with
STEC before and after BLV challenge, 3.4  1.2 in the group
treated after BLV challenge, 1.3  1.5 in the infection control
(BLV without STEC) group, and 1.9  1.4 in the healthy
control (no BLV) group. The difference between the group
treated before and after challenge and the infection control
group was significant (P  0.05) after the exclusion of animals
that lost weight. Two animals in the healthy control group lost
weight between 4 and 7 weeks, indicating that weight loss could
occur independently of BLV infection, and thus, a comparison
was made among weight-gaining animals only. The impact of
STEC treatment became apparent when weight change be-
tween 4 and 7 weeks post-BLV challenge was expressed as a
percentage (Fig. 7). Four animals in the group receiving treat-
ment prior to and post-BLV challenge and two animals in the
group receiving treatment only after challenge gained 10% or
more weight, while none of the animals in the infection control
FIG. 6. Suppression of BLV-induced syncytia correlated with total numbers of fecal STEC bacteria. Three experimental groups are shown that
were treated biweekly with oral doses of 5  1010 CFU bacteria/animal. Two groups received STEC, starting 2 weeks before BLV challenge (pre
& post BLV STEC, group 1) or starting 24 h post-BLV challenge (post BLV STEC, group 2) and continuing for 16 weeks post-BLV challenge.
The infection control group (BLV no STEC, group 3) received E. coli K-12 starting at week2. All groups were challenged with BLV. Fecal STEC
counts, averaged over a 2-month period post-BLV challenge and expressed as logarithms of CFU/g, are plotted against numbers of B cells per
syncytium. Horizontal solid lines at log 4 separate fecal STEC counts considered high (above log 4) and those considered low (below log 4). The
data points were optimally clustered in four quadrants as shown, using Pearson’s method to measure the distance between observations and
McQuitty’s linkage to measure the distance between clusters. Data points were fitted with cuboidal polynomial lines (R2 values shown) after the
exclusion of the outlier with fecal STEC numbers inconsistent with treatment (point in brackets) (A) and all group 3 points (B). Results were
obtained 3 weeks (A) and 3 months (B) post-BLV challenge.
FIG. 7. Fecal STEC numbers correlated with weight gain in sheep.
Four experimental groups are shown. Two groups received STEC
orally twice per week, starting 2 weeks before BLV challenge (pre &
post BLV STEC, group 1) or 24 h postchallenge (post BLV STEC,
group 2), until 16 weeks post-BLV challenge. The infection control
group (BLV no STEC, group 3) and the healthy control group (no
BLV, group 4) received E. coli K-12 starting at week 2, and the
healthy control group was not challenged with BLV. Weight gains
between 4 and 7 weeks post-BLV challenge are expressed as percent-
ages and plotted against average fecal STEC numbers post-BLV chal-
lenge. Arrows indicate animals from the infection control group (no
STEC BLV) that spontaneously acquired high fecal STEC counts after
BLV challenge.
VOL. 74, 2006 STEC BACTERIA MITIGATE BLV INFECTION IN SHEEP 2913
 o
n
 O
ctober 13, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
group gained as much (Fig. 7). Interestingly, BLV-infected and
STEC-treated sheep gained more weight than the animals in
the healthy control group, suggesting that STEC may promote
weight gain independently of viral infection. This supposition
was confirmed by analysis of the distribution of high fecal
STEC counts. When all 20 animals from four groups combined
were ranked by percentage of weight gain, the frequency of
total fecal STEC numbers of 104 CFU/g post-BLV challenge
was higher among the top 10 animals (15/20 or 75%) than
among the bottom 10 (7/20 or 35%) (chi-square test; P 0.05).
The animals in the infection control group gained less weight
than animals in the other groups, including the healthy control
sheep, suggesting that BLV challenge was associated with poor
weight gain and that this effect was counteracted by STEC
treatment. The protective effect appeared to be associated with
total fecal STEC counts of104 CFU/g. In both STEC-treated
groups, all six animals that presented with high counts of fecal
STEC bacteria gained 7% of weight post-BLV challenge,
whereas out of the four remaining animals with lower fecal
STEC numbers, three animals gained 7% of weight (Fig. 6).
Taken together, these results suggest that oral application of
STEC promoted weight gain in BLV-challenged sheep, espe-
cially when STEC treatment commenced before BLV chal-
lenge and when this treatment was associated with subsequent
total fecal STEC counts of 104 CFU/g.
DISCUSSION
The goal of this work was to determine whether intestinal
STEC bacteria have antiviral activity in vivo. To this end, we
compared the initial stages of BLV viremia among sheep ex-
perimentally infected with BLV and treated with oral applica-
tions of STEC or stx-negative E. coli. We showed that biweekly
oral STEC treatment reduced BLV viremia, although it did not
always result in consistently high fecal STEC numbers. This
STEC effect can be attributed to Stx and/or the presence of the
stx gene because treatment with an isogenic stx deletion mutant
did not have an antiviral effect. Also, the severity of viremia
was reduced in proportion to the total number of fecal STEC
bacteria, whether naturally occurring or from treatment. These
results support the hypothesis that in ruminants, intestinal
STEC bacteria have activity against BLV and possibly other
related viruses.
We chose to investigate the in vivo effects of STEC against
BLV because a substantial amount of previous work demon-
strates that Stx suppresses BLV replication in vitro (3, 16, 17).
The ovine model of BLV infection is commonly used in studies
of BLV biology and of host responses to this viral infection.
Major characteristics of BLV infection, such as incubation
period, disease symptoms, and cellular tropism of the virus, are
similar for cattle and sheep (22, 24, 45, 46). The noticeable
differences, including a faster progression of BLV-induced dis-
ease in sheep, susceptibility of sheep to lower challenge doses
(36, 48), and certain phenotypic differences between ovine and
bovine B-cell subpopulations undergoing BLV-induced expan-
sion in vivo (45), do not diminish the applicability of experi-
mental BLV infection in sheep to studies of viral disease and
host-virus interactions. Two clear advantages of the sheep
model are faster disease progression (months rather than
years) and easier animal handling.
BLV expression levels in vivo are similarly repressed in cat-
tle and sheep, presumably by the immune response. The clin-
ical picture before persistent lymphocytosis is that 1% of the
B cells are expressing viral proteins, the virus is predominantly
in a provirus form, and the amount of free virus in the blood
circulation is very small. However, viral expression is rapidly
derepressed in ex vivo cultures of purified PBMC from in-
fected animals (32, 33). To assess BLV viremia, we used two
well-established methods: measurements of SLP in PBMC cul-
tures and induction of syncytia in cocultures of PBMC and
F-81 indicator cells. Induction of syncytia by BLV is often used
to detect BLV (pro)virus in blood PBMC and is a more direct
method of viral measurement than SLP assessment (48, 53).
The tendency of purified PBMC from BLV-positive cattle to
spontaneously proliferate in culture is a hallmark of this infec-
tion (18, 49). BLV-induced SLP requires BLV expression by
cultured cells (51), and cell proliferation rates roughly corre-
late with the concentration of BLV particles, since the process
can be inhibited in a dose-dependent manner by monoclonal
antibody to a structural protein of BLV (17, 52). Although the
SLP rate may be affected by various factors (49), SLP of cul-
tures from infected sheep can be considered a measure of BLV
viremia.
Intestinal flora is a complex system of microbial communi-
ties characterized by host and spatial specificity with remark-
able stability and is refractory to change by external interven-
tions (21, 44). Therefore, it may not be surprising that oral
treatments with STEC, although substantial, had a limited
impact on the fecal STEC numbers in sheep and, in some
cases, even failed to bring a change in host status from fecal
STEC negative to fecal STEC positive. This inability to uni-
versally maintain fecal STEC numbers by oral treatment was
not dependent on bacterial strain and was observed with a
human isolate of E. coli O157:H7 (experiment I) and also with
five ovine STEC strains (experiment II). Such outcomes were
consistent with attempts by others to modify the composition
of the intestinal microbiota with oral bacteria that usually re-
sult only in transient changes (20).
Our data show that the fecal concentration of naturally oc-
curring STEC (i.e., in untreated animals) could exceed 104
CFU/g feces, consistent with published reports on the high
prevalence of intestinal STEC in sheep (4, 7, 31). The fact that
sheep can naturally carry STEC strains as transient members
of their normal intestinal microbiota was a complicating factor
in the design of our experiments and likely reduced the ob-
served differences in aftermaths of BLV challenge between
groups and confounded the analysis of the results. In spite of
that, STEC treatment had a clear, measurable, and often sta-
tistically significant effect on BLV viremia. Notably, a reduc-
tion of SLP and inhibition of syncytium formation correlated
with total fecal STEC numbers and were especially prominent
in STEC-treated sheep that presented with fecal STEC counts
of 104 CFU/g. Thus, the issue of naturally occurring STEC
could be addressed with an experimental design that foregoes
treatment with STEC and simply correlates fecal STEC num-
bers with reduced viremia. Although little information is avail-
able regarding the correlation between the total numbers of
STEC bacteria in feces and of bacteria expressing Stx in the
intestine, these results are consistent with such an assumption.
Our finding that the total numbers of naturally occurring
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STEC bacteria in sheep may reach concentrations of 106
CFU/g, whereas concentrations of 105 to 108 CFU/g are not
uncommon in cattle (19), indicates that ruminant animals are
likely to carry intestinal STEC at sufficient numbers for an
antiviral effect to occur.
A review of the literature uncovers a puzzling feature of BLV-
induced disease in experimentally infected sheep, namely, that
animals challenged with equal doses of infectious BLV often
present dissimilar B-cell alterations (46) and widely different BLV
loads in blood (8, 32, 56), even when littermates are compared
(33). Also, seroconversion times for infected sheep may range
from as little as 1 week (36) to 1 year (24). These inconsistencies
of experimental results may be related to the fact that BLV-
challenged sheep in the same experimental groups are likely to
carry different numbers and/or strains of intestinal STEC. Ac-
cordingly, our results suggest that the number and persistence
of intestinal STEC bacteria may account for this variability and
that determinations of fecal STEC numbers should be consid-
ered for experiments involving viral infections in animals that
routinely carry STEC.
Both Stx1 and Stx2 are able to translocate, via transcellular
transport, through the intact layer formed by cells of epithelial
intestinal cell lines (25, 41). Thus, it can be expected that the
toxins produced by intestinal STEC can gain access to the
intestinal lamina propria and to the systemic circulation. We
attribute the in vivo antiviral effect of STEC to the action of
Stxs translocating through the intestinal wall, entering highly
permeable, BLV-expressing cells, and selectively eliminating
these cells, as shown in vitro (3, 16). The toxin(s) may also
stimulate the lymphocytes and other immunocytes present in
the intestinal wall, systemic circulation, and lymphoid tissues.
Thus, it is conceivable that the mechanism of antiviral effect
observed in vivo may involve some indirect, toxin-mediated
immune responses. However, the fact that treatment with an
stx-negative isogenic mutant failed to induce responses com-
parable to those from treatment with wild-type bacteria sug-
gests that it is unlikely that products of STEC, other than Stxs,
are responsible for antiviral effects of STEC treatment. In
vitro, virally infected and Stx-intoxicated cells undergo a more
rapid demise than virally infected and not intoxicated cells
(unpublished data). This indicates that the antiviral effect me-
diated by Stxs occurs at the whole-animal level and involves the
elimination of virus-expressing cells, rather than rescue of cells
from viral infection by direct antiviral action or by induction of
an interferon system and other cellular antiviral remedies. The
mechanism of Stx antiviral effects was beyond the scope of this
study, but antiviral properties of RIPs are not necessarily lim-
ited to rRNA depurination. For example, some RIPs have
activity against reverse transcriptase and other viral proteins
(2, 38, 54), but such activities have yet to be described for Stxs.
The observation that STEC-treated animals infected with
BLV had better weight gain than the BLV-free control animals
not receiving STEC indicated that intestinal STEC bacteria
may confer physiological benefits to animal carriers. At least
three possible mechanisms may be involved: i) STEC may
synthesize nutritional microcomponents, ii) STEC may stimu-
late the host via interaction with the intestinal wall or com-
pounds delivered to the circulation, and iii) STEC may sup-
press growth of intestinal competitors detrimental to the host.
Since weight gain was unexpected, its mechanisms were not
investigated here but will be considered in future experiments.
Taken together, the results support the hypothesis that Stxs
produced by STEC in animal carriers have anti-BLV activities.
The fact that antiviral effects of STEC were especially promi-
nent when fecal STEC counts exceeded 104 CFU/g indicates
that intestinal colonization by high total numbers of STEC
bacteria was a strong factor in STEC-mediated antiviral effects.
It is conceivable that association between STEC strains and
their ruminant hosts confers a selective advantage for the lat-
ter, or for both, possibly by prolonging the life of a host and
thereby enhancing the dissemination of STEC in the environ-
ment. Such advantageous association could be a factor in the
high prevalence of stx in strains of E. coli found in ruminant
carriers. The results presented here are limited to the early
postchallenge manifestation of BLV infection and the begin-
ning of a chronic stage of the disease. Although it is clear that
intestinal STEC bacteria mitigate this initial phase of BLV-
induced disease, it remains to be determined whether STEC
can prevent or slow the disease progression to the lymphosar-
coma end stage and whether the described effect is applicable
to infections with other viruses.
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